Malta - anglų - Medicines Authority

genericon pharma gesellschaft m.b.h hafnerstrasse 211, 8054 graz, austria - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; iron oxide red; maleic acid; zinc stearate; iron oxide yellow; maize starch - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: hypromellose; maleic acid; iron oxide red; zinc stearate; maize starch; lactose monohydrate - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: maleic acid; zinc stearate; maize starch; hypromellose; lactose monohydrate - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - valaciclovir hydrochloride monohydrate, quantity: 1223.4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of opthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with altic, it is recommended that patients use safer sex practices (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - valaciclovir hydrochloride monohydrate, quantity: 611.7 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of opthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with altic, it is recommended that patients use safer sex practices (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - valaciclovir hydrochloride monohydrate, quantity: 305.85 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of opthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with altic, it is recommended that patients use safer sex practices (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; silica dimethyl silylate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; lactose monohydrate; microcrystalline cellulose; magnesium stearate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; magnesium stearate; microcrystalline cellulose; lactose monohydrate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.